Healthy Skepticism Library item: 9012
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Mori K.
[Introduction 'why is it multinational clinical trial now?']
Gan To Kagaku Ryoho. 2007 Feb; 34:(2):290-2
http://www.pier-online.jp/0385-0684/contents_abstract.php?serial_no=34020&seq=38
Abstract:
In spite of having developed first in Japan, we approved oxaliplatine last year behind Western countries with long delay. The problem of the drug lag in an anticancer drug is very serious, if you want to cancel somehow, now, is desperate, and considers this. Both regulatory authority and pharmaceutical industry approved of making the forum to which industry, academia and government meet together. Everyone on this first meeting, we should have a discussion from various angles and considered about the clinical development of an anticancer drug that the motion in recent years which is going to aim at world simultaneous development by multinational clinical trial with the West and the Asia neighboring countries wants to explore the way where our country can free itself from the situation of the circumference delay from the West at an early stage.
Keywords:
Publication Types:
English Abstract
MeSH Terms:
Antineoplastic Agents/therapeutic use*
Clinical Trials*
Drug Approval*
Drug Industry
Government
Humans
International Cooperation*
Multicenter Studies
Organoplatinum Compounds/therapeutic use*
Substances:
Antineoplastic Agents
Organoplatinum Compounds
oxaliplatin
Notes:
[Article in Japanese]
